U
Latigo Biotherapeutics, Inc. LTGO
$19.49 -$0.57-2.84% NASDAQ
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
--
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
--
Corporate Info
Phone Number
805 716 2927
Address
1300 Rancho Conejo Boulevard
Suite 305
Thousand Oaks, CA 91320
Country
United States
Year Founded
2018
Details
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Employees
--
Business Description
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.